Cardiology/Vascular Diseases | Phase III Developments | UNITED KINGDOM

Aerovate Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Aerovate Therapeutics Emerges From RA Capital Incubator With $72.6 Million Funding for Disease-Modifying Pulmonary Arterial Hypertension The...

Lead Product(s): Imatinib

Therapeutic Area: Cardiology/Vascular Diseases Product Name: AV-101

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: RA Capital Incubator

Deal Size: $72.6 million Upfront Cash: Undisclosed

Deal Type: Series A Financing August 06, 2020

Details:

Funding will advance trials of AV-101, an inhaled, dry powder aerosol version of imatinib to treat pulmonary arterial hypertension (PAH). An oral version of imatinib showed significant efficacy in a phase 3 trial as a disease-modifying therapy for PAH.

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

AZ Unveils Detailed Data from THALES Trial

Lead Product(s): Ticagrelor,Aspirin

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Brilinta

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 16, 2020

Details:

The Phase III THALES results shows that a combination of twice daily Brilinta (ticagrelor) and daily aspirin reduced the rate of stroke and death by 17% after 30 days compared to aspirin alone in patients with acute ischemic stroke or transient ischemic attack.

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

AstraZeneca's BRILINTA Gets FDA Priority Review for the Reduction of Subsequent Stroke Acute Ischemic Stroke Patients

Lead Product(s): Ticagrelor,Aspirin

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Brilinta

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 09, 2020

Details:

Phase III THALES trial showed aspirin plus BRILINTA 90mg used twice daily for 30 days, resulted in a statistically significant and clinically meaningful reduction in the risk of the primary composite endpoint of stroke and death, compared to aspirin alone.

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

BRILINTA Met Primary Endpoint in the Phase III THALES Trial in Stroke

Lead Product(s): Ticagrelor,Aspirin

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 27, 2020

Details:

BRILINTA reduced the risk of the composite of stroke and death after an acute ischemic stroke or transient ischemic attack.

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

FARXIGA Granted FDA Priority Review For Patients With Heart Failure With Reduced Ejection Fraction

Lead Product(s): Dapagliflozin

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 06, 2020

Details:

The sNDA was based on results from the landmark Phase III DAPA-HF trial, which showed FARXIGA reduced the incidence of the composite outcome of CV death or the worsening of HF versus placebo.

Find

Find Drugs for Cardiology/Vascular Diseases in Phase III Clinical Development in UNITED KINGDOM

United Kingdom

Product Type

Companies

Aerovate Therapeutics

Aerovate Therapeutics Emerges From RA Capital Incubator With $72.6 Million Funding for Disease-Modifying Pulmonary Arterial Hypertension The...

AstraZeneca PLC

AZ Unveils Detailed Data from THALES Trial

AstraZeneca PLC

AstraZeneca's BRILINTA Gets FDA Priority Review for the Reduction of Subsequent Stroke Acute Ischemic Stroke Patients

AstraZeneca PLC

BRILINTA Met Primary Endpoint in the Phase III THALES Trial in Stroke

AstraZeneca PLC

FARXIGA Granted FDA Priority Review For Patients With Heart Failure With Reduced Ejection Fraction